Pulmatrix Q2 loss narrows on clinical development hold

Pulmatrix

13/08/2026 13:26

Overview
U.S. biopharma firm's Q2 net loss narrowed as general and administrative expenses declined
All clinical development on hold as company seeks to license or monetize clinical assets
Company focused on completing proposed merger with Eos SENOLYTIX in Q3 2026

Outlook
Company expects proposed merger with Eos SENOLYTIX to close in Q3 2026
All clinical development on hold while company seeks to license or monetize clinical assets
Pulmatrix anticipates cash position is sufficient to fund operations through expected merger closing

Result Drivers
MERGER FOCUS - Co said it prioritized advancing steps toward completing proposed merger with Eos SENOLYTIX
CLINICAL DEVELOPMENT ON HOLD - All clinical development is currently on hold while co works to license or monetize clinical assets
LOWER OPERATING COSTS - General and administrative expenses fell due to lower software, legal, patent, and merger-related costs

Company press release: ID:nPn5QNHYna

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.29
 

Reuters Recommended Reads
Aug 11 - Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aug 13 - Artelo Biosciences Q2 net loss narrows as R&D expenses fall
Aug 12 - Eloxx Pharmaceuticals Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)